Certain drug therapies, such as heparin, warfarin, and aspirin, are associated with prothrombotic or hypercoagulable states. If these agents that are administered to prevent thrombosis have been associated with its opposite effect, then agents that are specifically given to inhibit bleeding may produce a deleterious hypocoagulable effect. This article evaluates the risks presented by serine protease inhibitors (ie, aprotinin), lysine analog antifibrinolyics (ie, epsilon aminocaproic acid [Amicar, Wyeth-Ayerst, Philadelphia, PA] and tranexamic acid), and desmopressin acetate (DDAVP, Rhone-Poulenc Rorer, Collegeville, PA). It focuses on their mechanisms of action, particularly their effect on microvascular tone and endothelial function, coagulation factors, platelet function, and the fibrinolytic pathway. It discusses their use in the presence of known thrombin production or fibrinogen conversion and whether certain vascular beds are more prone to drug-related thrombosis.
Get full access to this article
View all access options for this article.
References
1.
Schramm W., Spannagl M., Bauer KA, et al: Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch Dermatol129:753-756, 1993
2.
Soundararajan R., Leehey DJ, Yu AW, et al: Skin necrosis and protein C deficiency associated with vitamin K depletion in a patient with renal failure. Am J Med93:467-470, 1992
3.
Hirsh J.: Oral anticoagulant drugs. N Engl J Med324:1865-1875, 1991
4.
Iguchi A., Sato K.: Protein C response to induction of warfarin treatment after coronary bypass operation. Thorac Cardiovasc Surg42:222-224, 1994
5.
Royston D.: High-dose aprotinin therapy: A review of the first five years' experience . J Cardiothorac Vasc Anesth6:76-100, 1992
6.
Royston BD, Royston D., Coade SB, et al: Aprotinin does not inhibit the release of PGI2 or vWF from cultured human endothelial cells. Thromb Haemost67:172-175, 1992
7.
Havel MP, Griesmacher A., Weigel G., et al: Aprotinin decreases release of 6-keto-prostaglandin F1 alpha and increases release of thromboxane B2 in cultured human umbilical vein endothelial cells. J Thorac Cardiovasc Surg104:654-658, 1992
8.
Dejana E., Cazenave JP, Groves HM, et al: The effect of aspirin inhibition of PGI2 production on platelet adherence to normal and damaged rabbit aortae. Thromb Res17:453-464,1980
9.
Czervionke RL , Hoak JC, Fry GL: Effect of aspirin on thrombin-induced adherence of platelets to cultured cells from the blood vessel wall. J Clin Invest62:847-856, 1978
10.
Havel MP, Griesmacher A., Weigel G., et al: Aprotinin increases release of von Willebrand factor in cultured human umbilical vein endothelial cells. Surgery112:573-577, 1992
11.
Espana F., Estelles A., Griffin JH, et al: Aprotinin (Trasylol) is a competitive inhibitor of activated protein C. Thromb Res56:751-756,1989
12.
Taby O., Chabbat J., Steinbuch M.: Inhibition of activated protein C by aprotinin and the use of the insolubilized inhibitor for its purification. Thromb Res59:27-35, 1990
13.
Boldt J., Schindler E., Knothe C., et al: Does aprotinin influence endothelial-associated coagulation in cardiac surgery?J Cardiothorac Vasc Anesth8:527-531, 1994
14.
Boldt J., Zickmann B., Schindler E., et al: Influence of aprotinin on the thrombomodulin/protein C system in pediatric cardiac operations. J Thorac Cardiovasc Surg107:1215-1221, 1994
15.
Boldt J., Schindler E., Welters I., et al: The effect of the anticoagulation regimen on endothelial-related coagulation in cardiac surgery patients. Anaesthesia50:954-960, 1995
16.
Feindt P., Volkmer I., Seyfert UT, Haack H.: The role of protein C as an inhibitor of blood clotting during extracorporeal circulation. Thorac Cardiovasc Surg39: 338-343, 1991
17.
Robbins P., Forrest M., Fanning S., Royston D.: Use of aprotinin therapy in a patient with factor V Leiden. Anesth Analg84:694-698, 1997
18.
Allen S., Anastasian N., Royston D., et al: Effect of aprotinin on vascular reactivity of coronary artery bypass grafts. J Thorac Cardiovasc Surg113:319-326, 1997
19.
Fritz H., Wunderer G.: Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung33:479-494, 1983
20.
Guidetti B. , Spallone A.: The role of antifibrinolytic therapy in the preoperative management of recently ruptured intracranial aneurysms . Surg Neurol15:239-248,1981
21.
Spallone A. : Antifibrinolytics in aneurysmal subarachnoid haemorrhage. A retrospective comparison of two different forms of antifibrinolytic therapy. Acta NeurochirWien63:245-250, 1982
Protease inhibitors for delayed cerebral ischemia after subarachnoid haemorrhage? Lancet339:1199-1200, 1992 (editorial)
24.
Yanamoto H. , Kikuchi H., Sato M., et al: Therapeutic trial of cerebral vasospasm with the serine protease inhibitor, FUT-175, administered in the acute stage after subarachnoid hemorrhage. Neurosurgery30:358-363, 1992
25.
Yanamoto H. , Kikuchi H., Okamoto S., Nozaki K.: Preventive effect of synthetic serine protease inhibitor, FUT-175, on cerebral vasospasm in rabbits. Neurosurgery30:351-356, 1992
26.
Tweddell J. , Berger S., Frommelt P., et al: Aprotinin improves outcome of single-ventricle palliation. Ann Thorac Surg62:1329-1336, 1996
27.
Goldstein DJ , Seldomridge JA, Chen JM, et al: Use of aprotinin in LVAD recipients reduces blood loss, blood use, and perioperative mortality . Ann Thorac Surg59:1063-1067,1995
28.
Prendergast T., Furukawa S., Beyer J., et al: Defining the role of aprotinin in heart transplantation. Ann Thorac Surg62:670-674, 1996
29.
Hill G., Taylor J., Robbins R.: Differing effects of aprotinin and epsilon-aminocaproic acid on cytokine-induced inducible nitric oxide synthase expression. Ann Thorac Surg63:74-77, 1997
30.
Royston BD, Royston D., Pearson JD: Aprotinin inhibits platelet adhesion to endothelial cells. Blood Coagul Fibrinolysis3:737-742, 1992
31.
Tam EK, Franconi GM, Nadel JA, Caughey GH: Protease inhibitors potentiate smooth muscle relaxation induced by vasoactive intestinal peptide in isolated human bronchi. Am J Respir Cell Mol Biol2:449-452, 1990
32.
Green D., Ts'ao CH, Cerullo L., et al: Clinical and laboratory investigation of the effects of epsilon-aminocaproic acid on hemostasis. J Lab Clin Med105:321-327, 1985
33.
Takahashi H. , Koike T., Yoshida N., et al: Excessive fibrinolysis in suspected amyloidosis: Demonstration of plasmin-alpha 2-plasmin inhibitor complex and von Willebrand factor fragment in plasma. Am J Hematol23:153-166,1986
34.
Garrett J., Branco D.: Indirect sympathomimetic actions of epsilon-aminocaproic acid (EACA): Role of the adrenal medulla. Arch Int Pharmacodyn Ther204:252-259,1973
35.
Barry KJ, Selland BA, Stein BM: The effects of epsilon aminocaproic acid on contractile properties and catecholamine content of rat carotid arteries. Surg Neurol17:273-278, 1982
36.
Reis CC, Scivoletto R.: Stores of catecholamines involved in sympathomimetic activity of epsilon-aminocaproic acid. Gen Pharmacol10:207-213, 1979
37.
Hoie J., Sykes BJ, Schenk W.Jr: The influence of epsilon aminocaproic acid on cardiac performance. An experimental study in dogs. J Thorac Cardiovasc Surg62:255-261, 1971
38.
Ameen AA, Illingworth R.: Antifibrinolytic treatment in the preoperative management of subarachnoid haemorrhage caused by ruptured intracranial aneurysm. J Neurol Neurosurg Psychiatry44:220-226. 1981
Fodstad H., Forssell A., Liliequist B. Schannong M: Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: A consecutive controlled clinical trial. Neurosurgery8:158-165, 1981
41.
Fodstad H.: Antifibrinolytic treatment in subarachnoid haemorrhage: Present state . Acta NeurochirWien63: 233-244, 1982
42.
Fodstad H., Liliequist B.: Spontaneous thrombosis of ruptured intracranial aneurysms during treatment with tranexamic acid (AMCA). Report of three cases. Acta NeurochirWien49:129-144, 1979
Scott RM, Garrido E.: Spontaneous thrombosis of an intracranial aneurysm during treatment with epsilon aminocaproic acid. Surg Neurol7:21-23, 1977
45.
Tanghetti B. , Capra R., Marini G.: Spontaneous thrombosis of ruptured intracranial aneurysm during treatment with tranexamic acid. Case report. J Neurosurg Sci29:105-108,1985
46.
Tsementzis SA, Hitchcock ER, Meyer CH: Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. Acta NeurochirWien102:1-10, 1990
47.
Tsementzis SA, Meyer CH, Hitchcock ER: Cerebral blood flow in patients with a subarachnoid haemorrhage during treatment with tranexamic acid. Neurochirurgia Stuttg35:74-78, 1992
48.
Yamaura A., Nakamura T., Makino H., Hagihara Y.: Cerebral complication of antifibrinolytic therapy in the treatment of ruptured intracranial aneurysm. Animal experiment and a review of literature . Eur Neurol19:77-84,1980
49.
Glick R., Green D., Ts'ao C., et al: High-dose epsilon-aminocaproic acid prolongs the bleeding time and increases rebleeding and intraoperative hemorrhage in patients with subarachnoid hemorrhage. Neurosurgery9:398-401,1981
50.
MacGregor IR , Roberts EM, Prowse CV, et al: Fibrinolytic and haemostatic responses to desamino-D-arginine vasopressin (DDAVP) administered by intravenous and subcutaneous routes in healthy subjects. Thromb Haemost59:34-39, 1988
51.
D'Alauro FS , Johns RA: Hypotension related to desmopressin administration following cardiopulmonary bypass. Anesthesiology69:962-963, 1988
52.
Reich DL, Hammerschlag BC, Rand JH, et al: Desmopressin acetate is a mild vasodilator that does not reduce blood loss in uncomplicated cardiac surgical procedures. J Cardiothorac Vasc Anesth5:142-145, 1991
53.
Salmenpera M., Kuitunen A., Hynynen M.; Heinonen J.: Hemodynamic responses to desmopressin acetate after CABG: A double-blind trial. J Cardiothorac Vasc Anesth5:146-149,1991
54.
Jahr JS, Marquez J., Cottington E., Cook DR: Hemodynamic performance and histamine levels after desmopressin acetate administration following cardiopulmonary bypass in adult patients. J Cardiothorac Vasc Anesth5:139-141, 1991
55.
Bichet DG, Razi M., Lonergan M., et al: Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus. N Engl J Med318:881-887, 1988
56.
Harke H., Gennrich M.: [Aprotinin-ACD-blood: I. Experimental studies on the effect of aprotinin on the plasmatic and thrombocytic coagulation (author's transl)]. Anaesthetist29:266-276, 1980
57.
Aramoto H., Saito H., Shigematsu H., Muto T.: [Synthetic protease inhibitors in the treatment of disseminated intravascular coagulation]. Nippon Rinsho51:93-98, 1993
58.
Gando S., Tedo I.: [An analysis of DIC in patients with multiple organ failure-variations of the molecular makers and its clinical usefulness]. Rinsho Ketsueki31:1774-1779, 1990
59.
Kumon K., Tanaka K., Nakajima N., et al: Anticoagulation with a synthetic thrombin inhibitor after cardiovascular surgery and for treatment of disseminated intravascular coagulation. Crit Care Med12:1039-1043, 1984
60.
Matsuda T., Iwata H., Noda H., et al: Antithrombogenic elastomers: Novel anticoagulant/complement inhibitor-controlled release systems. Trans Am Soc Artif Intern Organs31:244-249, 1985
61.
Matsuo T., Kario K., Nakao K., et al: Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk. Haemostasis23:135-141, 1993
62.
de Smet AA, Joen MC, van Oeveren W., et al: Increased anticoagulation during cardiopulmonary bypass by aprotinin . J Thorac Cardiovasc Surg100:520-527, 1990 (see comments)
63.
Despotis GJ , Alsoufiev A., Goodnough LT, Lappas DG: Aprotinin prolongs whole blood activated partial thromboplastin time but not whole blood prothrombin time in patients undergoing cardiac surgery. Anesth Analg81:919-924, 1995
64.
Chabbat J., Porte P., Tellier M., Steinbuch M.: Study of different human and animal thromboplastins with human factor VIIa in the presence of aprotinin. Thromb Res77:387-392, 1995
65.
Chabbat J., Porte P., Tellier M., Steinbuch M.: Aprotinin is a competitive inhibitor of the factor VIIa-tissue factor complex . Thromb Res71:205-215, 1993
66.
Burman JF, Chung HI, Lane DA, et al: Role of factor XII in thrombin generation and fibrinolysis during cardiopulmonary bypass. Lancet344:1192-1193, 1994
67.
Boisclair MD , Lane DA, Philippou H., et al: Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood82:3350-3357, 1993
68.
Haas S., Ketterl R., Stemberger A., et al: The effect of aprotinin on platelet function, blood coagulation and blood lactate level in total hip replacement—A double-blind clinical trial. Adv Exp Med Biol167:287-297, 1984
69.
Ketterl R., Haas S., Lechner F., et al: [Effect of aprotinin on thrombocytic function during total endoprosthesis surgery of the hip]. Med Welt31:1239-1243, 1980
70.
Ketterl R., Haas S., Heiss A., et al: [Effect of the natural proteinase inhibitor aprotinin on platelet function in allo-arthroplastic hip replacement]. Med Welt33:480-486, 1982
71.
Laskowski M. , Kato I.: Protein inhibitors of proteinases. Ann Rev Biochem49:593-626, 1980
72.
Blauhut B., Harringer W., Bettelheim P., et al: Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. J Thorac Cardiovasc Surg108:1083-1091, 1994
73.
Freise J., Magerstedt P., Schmid K.: Inhibition of phospholipase A2 by gabexate mesilate, camostate and aprotinin . Enzyme30:209-212, 1983
74.
Freise J., Wittenberg H., Magerstedt P.: In vitro inhibition of phospholipase A2 by gabexate mesilate, camostate, and aprotinin. Klin Wochenschr67:149-152, 1989
75.
Blauhut B., Gross C., Necek S., et al: Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass . J Thorac Cardiovasc Surg101:958-967, 1991
76.
Nagaoka H., Innami R., Murayama F., et al: Effects of aprotinin on prostaglandin metabolism and platelet function in open heart surgery. J Cardiovasc Surg Torino32:31-37, 1991
77.
Nagaoka H., Innami R., Funakoshi N., et al: [Arachidonic acid metabolism and effectiveness of aprotinin treatment during cardiopulmonary bypass]. Nippon Kyobu Geka Gakkai Zasshi39:1723-1730, 1991
78.
Soslau G., Horrow J., Brodsky I.: Effect of tranexamic acid on platelet ADP during extracorporeal circulation . Am J Hematol38:113-119, 1991
79.
Zeigler ZR: Effects of epsilon aminocaproic acid on primary hemostasis. Haemostasis21:313-320, 1991
80.
Schulman S. , Johnsson H., Egberg N., Blomback M.: DDAVP-induced correction of prolonged bleeding time in patients with congenital platelet function defects. Thromb Res45:165-174, 1987
81.
Dilthey G., Dietrich W., Spannagl M., Richter JA: Influence of desmopressin acetate on homologous blood requirements in cardiac surgical patients pretreated with aspirin. J Cardiothorac Vasc Anesth7:425-430, 1993
82.
van Hinsbergh VW: Regulation of the synthesis and secretion of plasminogen activators by endothelial cells. Haemostasis18:307-327, 1988
83.
Weitz JI, Leslie B.: Urokinase has direct catalytic activity against fibrinogen and renders it less clottable by thrombin. J Clin Invest86:203-212, 1990
84.
Moroz LA, Gilmore NJ: Fibrinolysis in normal plasma and blood: Evidence for significant mechanisms independent of the plasminogen-plasmin system. Blood48:531-545,1976
85.
Weitz JI, Leslie B., Hirsh J., Klement P.: Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis. J Clin Invest91:1343-1350, 1993
86.
Fears R., Greenwood J., Hearn J., et al: Inhibition of the fibrinolytic and fibrinogenolytic activity of plasminogen activators in vitro by the antidotes e-aminocaproic acid, tranexamic acid and aprotinin. Fibrinolysis6:79-86, 1992
87.
Garabedian HD, Gold HK, Leinbach RC, et al: Bleeding time prolongation and bleeding during infusion of recombinant tissue-type plasminogen activator in dogs: Potentiation by aspirin and reversal with aprotinin. J Am Coll Cardiol17:1213-1222, 1991
88.
de Bono D., Pringle S., Underwood I.: Differential effects of aprotinin and tranexamic acid on cerebral bleeding and cutaneous bleeding time during rt-PA infusion. Thromb Res61:159-163, 1991
89.
Spannagl M. , Dooijewaard G., Dietrich W., Kluft C.: Protection of single-chain urokinase-type plasminogen activator (scu-PA) in aprotinin-treated cardiac surgical patients undergoing cardiopulmonary bypass. Thromb Haemost73:825-828, 1995
90.
Himmelreich G., Dooijewaard G., Breinl P., et al: Changes in urokinase-type plasminogen activator in orthotopic liver transplantation. Semin Thromb Hemost19:311-314,1993
91.
Himmelreich G., Dooijewaard G., Neuhaus P., et al: Increased urokinase-type plasminogen activator (u-PA) levels in graft liver perfusate and decreased single-chain u-PA activation with higher levels of aprotinin. Thromb Haemost71:12-14, 1994
92.
Lu H., Du Buit C., Soria J., et al: Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy. Thromb Haemost72:438-443, 1994
93.
Liu B., Tengborn L., Larson G., et al: Half-dose aprotinin preserves hemostatic function in patients undergoing bypass operations. Ann Thorac Surg59:1534-1540,1995
94.
Grosse H., Lobbes W., Frambach M., et al: The use of high-dose aprotinin in liver transplantation: The influence on fibrinolysis and blood loss. Thromb Res63:287-297, 1991
Kawamura H. , Watanabe I., Urano T., et al: The effects of polysaccharides on plasminogen activation by single-chain and two-chain tissue plasminogen activator . Thromb Res62:481-490, 1991
97.
Fish KJ, Sarnquist FH, van Steennis C., et al: A prospective, randomized study of the effects of prostacyclin on platelets and blood loss during coronary bypass operations. J Thorac Cardiovasc Surg91:436-444, 1986
98.
Despotis G. , Joist J., Hogue C., et al: The effect of higher heparin concentrations on preservation of hemostasis in cardiac surgical patients. Anesthesiology83:A91, 1995 (abstract)
99.
Royston D.: Coagulation in cardiac surgery. Adv Card Surg8:19-45, 1996
100.
Moorehead M., Westernguard J., Bull B.: Platelet involvement in the activated coagulation time of heparinized blood. Anesth Analg63:394-398, 1984
101.
Bode AP, Castellani WJ, Hodges ED, Yelverton S.: The effect of lysed platelets on neutralization of heparin in vitro with protamine as measured by the activated coagulation time (ACT) [published erratum appears in Thromb Haemost Dec 2;66:746, 1991]. Thromb Haemost66:213-217, 1991
102.
Dietrich W. , Spannagl M., Jochum M., et al: Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization . Anesthesiology73:1119-1126, 1990
103.
Clozel JP, Banken L., Roux S.: Aprotinin: An antidote for recombinant tissue-type plasminogen activator (rt-PA) active in vivo.J Am Coll Cardiol16:507-510, 1990
104.
Akhtar TM, Goodchild CS, Boylan MK: Reversal of streptokinase-induced bleeding with aprotinin for emergency cardiac surgery. Anaesthesia47:226-228, 1992
105.
Efstratiadis T., Munsch C., Crossman D., Taylor K.: Aprotinin used in emergency coronary operation after streptokinase treatment. Ann Thorac Surg52:1320-1321, 1991 (comments)
106.
Schneider J.: Interactions of saruplase with acetylsalicylic acid, heparin, glyceryl trinitrate, tranexamic acid and aprotinin in a rabbit pulmonary thrombosis model. Arzneimittelforschung40:1180-1184, 1990
107.
Markland FS , Friedrichs GS, Pewitt SR, Lucchesi BR: Thrombolytic effects of recombinant fibrolase or AP-SAC in a canine model of carotid artery thrombosis. Circulation90:2448-2456, 1994
108.
Wiman B.: On the reaction of plasmin or plasmin-streptokinase complex with aprotinin or alpha 2-antiplasmin. Thromb Res17:143-152, 1980
109.
Westlund LE , Lunden R., Wallen P.: Effect of EACA, PAMBA, AMCA and AMBOCA on fibrinolysis induced by streptokinase, urokinase and tissue activator. Haemostasis11:235-241, 1982
110.
Lijnen HR, Stassen JM, Collen D.: Differential inhibition with antifibrinolytic agents of staphylokinase- and streptokinase-induced clot lysis. Thromb Haemost73:845-849, 1995
111.
Tytgat G., Collen D., Verstraete M.: Metabolism of fibrinogen in cirrhosis of the liver. J Clin Invest50:1690-1701, 1971
112.
Prah GN, Lisman SR, Maslow AD, et al: Transesophageal echocardiography reveals an unusual cause of hemodynamic collapse during orthotopic liver transplantation—Two case reports. Transplantation59:921-925, 1995
113.
Baubillier E., Cherqui D., Dominique C., et al: A fatal thrombotic complication during liver transplantation after aprotinin administration. Transplantation57:1664-1666,1994
114.
De Wolf A. , Gologorsky E., Scott V.: Intravascular and intracardiac thrombus formation and pulmonary thromboembolism immediately after graft reperfusion in six patients undergoing liver transplantation. Liver Transplant Surg1:416-420, 1995
115.
Graeff H., Holzmann K., Gokel JM, et al: [Pathomechanisms, signs, symptoms and management of amniotic fluid embolism (author's transl)]. Geburtshilfe Frauenheilkd38:887-894, 1978
116.
Sher G.: The diagnosis and management of accidental haemorrhage with associated coagulopathy . S Afr Med J49:1383-1386, 1975
117.
Sher G.: Trasylol in the management of abruptio placentae with consumption coagulopathy and uterine inertia. J Reprod Med25:113-118, 1980
118.
Sher G., Statland BE: Abruptio placentae with coagulopathy: A rational basis for management . Clin Obstet Gynecol28:15-23, 1985
Abe T., lyomasa Y., Murase M., et al: A case of bacteremia and disseminated intravascular coagulation after the conduit procedure for tetralogy of Fallot with pulmonary atresia . Jpn Circ J46:1098-1104, 1982
121.
Kolbow H., Barthels M., Oestern HJ, et al: [Early changes of the coagulation system in multiple injuries and their modification with heparin and Trasylol]. Chir Forum Exp Klin Forsch April(2):119-123, 1977
122.
Kotschy M. , Kotlarek Haus S., Podolak Dawidziak M., et al: Intravascular coagulation and fibrinolysis syndrome (ICF) in acute non-promyelocytic leukemia . Folia Haematol Int Mag Klin Morphol Blutforsch107:65-73, 1980
123.
Mateva L., Donkova O.: [The protease inhibitor treatment of the disseminated intravascular coagulation syndrome in patients with liver cirrhosis]. Vutr Boles30:105-110, 1991
124.
Mora A., Cortes C., Roige J., et al: [Orthotopic liver transplant for giant cavernous hemangioma and Kasabach-Merritt syndrome]. Rev Esp Anestesiol Reanim42:71-74,1995
125.
Saito H.: [Treatment of obstetrical disseminated intravascular coagulation—Sequential changes of coagulation and fibrinolytic system in DIC rabbits]. Nippon Sanka Fujinka Gakkai Zasshi35:507-516, 1983
126.
Palmer JD, Francis DA, Roath OS, et al: Hyperfibrinolysis during intracranial surgery: Effect of high-dose aprotinin. J Neurol Neurosurg Psychiatry58:104-116, 1995
127.
Gaszynski W.: The use of protease inhibitor (trasylol) and heparin in cardiorespiratory resuscitation. I. Studies of the blood clotting system. Anaesth Resusc Intensive Ther3:125-134, 1975
128.
Jochum M., Witte J., Schiessler H., et al: Clotting and other plasma factors in experimental endotoxemia: Inhibition of degradation by exogenous proteinase inhibitors. Eur Surg Res13:152-168, 1981
129.
Moriau M., Rodhain J., Noel H., et al: Comparative effects of proteinase inhibitors, plasminogen antiactivators, heparin and acetylsalicylic acid on the experimental disseminated intravascular coagulation induced by thrombin. Thromb Diath Haemorrh32:171-188, 1974
130.
Svanberg L. , Astedt B., Nilsson IM: Abruptio placentae— Treatment with the fibrinolytic inhibitor tranexamic acid. Acta Obstet Gynecol Scand59:127-130, 1980
131.
Becker J., Borgstrom S.: Incidence of thrombosis associated with epsilon-aminocaproic acid administration and with combined epsilon-aminocaproic acid and subcutaneous heparin therapy. A study in experimental animals and in clinical material . Acta Chir Scand134:343-349, 1968
132.
Becker J., Borgstrom S., Saltzman GF: Incidence of thrombosis associated with epsilon-aminocaproic acid administration and with combined epsilon-aminocaproic acid and subcutaneous heparin therapy. II. A clinical study with the aid of intravenous phlebography . Acta Chir Scand136:167-171, 1970
133.
Gralnick HR , Greipp P.: Thrombosis with epsilon aminocaproic acid therapy. Am J Clin Pathol56:151-154, 1971
134.
Bekassy Z. , Astedt B.: Treatment with the fibrinolytic inhibitor tranexamic acid—Risk for thrombosis?Acta Obstet Gynecol Scand69:353-354, 1990 (letter)
135.
Brooke CP, Spiers EM, Omura EF: Noninflammatory bullae associated with epsilon-aminocaproic acid infusion . J Am Acad Dermatol27:880-882, 1992
136.
Tubbs RR, Benjamin SP, Dohn DE: Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis. Case report. J Neurosurg51:94-97, 1979
137.
Dentz ME, Slaughter TF, Mark JB: Early thrombus formation on heparin-bonded pulmonary artery catheters in patients receiving epsilon aminocaproic acid. Anesthesiology82:583-586, 1995
138.
Hocker JR, Saving KL: Fatal aortic thrombosis in a neonate during infusion of epsilon-aminocaproic acid. J Pediatr Surg30:1490-1492, 1995
139.
Cosgrove D. IIIrd, Heric B., Lytle BW, et al: Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study. Ann Thorac Surg54:1031-1036, 1992
140.
Umbrain V. , Christiaens F., Camu F.: Intraoperative coronary thrombosis: Can aprotinin and protamine be incriminated?J Cardiothorac Vasc Anesth8:198-201, 1994 (comments)
141.
Bohrer H., Fleischer F., Lang J., Vahl C.: Early formation of thrombi on pulmonary artery catheters in cardiac surgical patients receiving high-dose aprotinin. J Cardiothorac Anesth4:222-225, 1990 (comments)
142.
Gitter R., Alivizators P., Capehart J., et al: Aprotinin and aortic cannula thrombosis. J Thorac Cardiovasc Surg112:537-538, 1996
143.
Smith P., Muhlbaier L.: Aprotinin: Safe and effective only with the full-dose regimen. Ann Thorac Surg62:1575-1577, 1996
144.
Coffey A., Pittmam J., Halbrook H., et al: The use of tranexamic acid to reduce postoperative bleeding following cardiac surgery: A double-blind randomized trial. Am Surg61:566-568,1995
145.
Horrow JC, Van Riper DF, Strong MD, et al: The dose-response relationship of tranexamic acid. Anesthesiology82:383-392, 1995
146.
Karski JM, Teasdale SJ, Norman PH, et al: Prevention of postbypass bleeding with tranexamic acid and epsilon-aminocaproic acid. J Cardiothorac Vasc Anesth7:431-435, 1993
147.
Karski JM, Teasdale SJ, Norman P., et al: Prevention of bleeding after cardiopulmonary bypass with high-dose tranexamic acid. Double-blind, randomized clinical trial. J Thorac Cardiovasc Surg110:835-842, 1995
148.
Katsaros D. , Petricevic M., Snow NJ, et al: Tranexamic acid reduces postbypass blood use: A double-blinded, prospective, randomized study of 210 patients . Ann Thorac Surg61:1131-1135, 1996
149.
Ovrum E., Am Holen E., Abdelnoor M., et al: Tranexamic acid (Cyklokapron) is not necessary to reduce blood loss after coronary artery bypass operations. J Thorac Cardiovasc Surg105:78-83, 1993
150.
Rousou JA, Engelman RM, Flack JE IIIrd, et al: Tranexamic acid significantly reduces blood loss associated with coronary revascularization. Ann Thorac Surg59: 671-675, 1995
151.
Yau TM, Carson S., Weisel RD, et al: The effect of warm heart surgery on postoperative bleeding. J Thorac Cardiovasc Surg103:1155-1162, 1992
152.
Hammermeister KE, Burchfiel C., Johnson R., Grover FL: Identification of patients at greatest risk for developing major complications at cardiac surgery. Circulation82:IV380-389, 1990 (suppl 5)
153.
Roach G., Kanchuger M., Mangano C., et al: Adverse cerebral outcomes after coronary bypass surgery. N Engl J Med335:1857-1863,1996
154.
Hayhurst MD : Extensive thrombosis following central venous catheterization—A relationship to antifibrinolytic therapy?S Afr Med J63:797, 1983 (letter)
155.
Youngberg JA: Aprotinin and thrombus formation on pulmonary artery catheters: A piece of the coagulation puzzle. J Cardiothorac Anesth4:155-158, 1990 (ed comment)
156.
MacIomhair M., Lavelle SM: Thrombus weight as a measure of hypercoagulability induced by drugs. Thromb Haemost42:1018-1021, 1979
157.
Tuman K., Spiess B., McCarthy R., Ivankovich A.: Effects of progressive blood loss on coagulation as measured by thrombelastography . Anesth Analg66:856-863, 1987
158.
Latour JG, Leger Gauthier C., Daoust Fiorilli J.: Vasoactive agents and production of thrombosis during intravascular coagulation 1—Comparative effects of norepinephrine in thrombin and adenosine diphosphate (ADP)-treated rabbits. Pathology16:411-417, 1984
159.
Arnljots B. , Wieslander JB, Dougan P., Salemark L.: Importance of fibrinolysis in limiting thrombus formation following severe microarterial trauma: An experimental study in the rabbit. Microsurgery12:332-339, 1991
160.
DelRossi AJ , Cernaianu AC, Botros S., et al: Prophylactic treatment of postperfusion bleeding using EACA. Chest96:27-30, 1989
161.
Lemmer J., Dilling E., Morton J., et al: Aprotinin for primary coronary artery bypass grafting: A multicenter trial of three dose regimens. Ann Thorac Surg62:1659-1668, 1996
162.
Royston D. : Intraoperative coronary thrombosis: Can aprotinin be incriminated?J Cardiothorac Vasc Anesth8:137-141, 1994
